The UBS Asset Management Americas Inc. Has $750,000 Position in Natus Medical Inc. (BABY)

The UBS Asset Management Americas Inc. Has $750,000 Position in Natus Medical Inc. (BABY)

UBS Asset Management Americas Inc. increased its stake in shares of Natus Medical Inc. (NASDAQ:BABY) by 8.5% during the third quarter, according to its most recent filing with the SEC. The fund owned 19,099 shares of the company’s stock after buying an additional 1,500 shares during the period. UBS Asset Management Americas Inc. owned approximately 0.06% of Natus Medical worth $750,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BABY. Bank of Montreal Can bought a new stake in shares of Natus Medical during the second quarter valued at approximately $1,919,000. Strs Ohio boosted its stake in shares of Natus Medical by 8.3% in the second quarter. Strs Ohio now owns 26,200 shares of the company’s stock valued at $990,000 after buying an additional 2,000 shares during the last quarter. Moody Aldrich Partners LLC boosted its stake in shares of Natus Medical by 125.9% in the second quarter. Moody Aldrich Partners LLC now owns 34,760 shares of the company’s stock valued at $1,314,000 after buying an additional 19,375 shares during the last quarter. Confluence Investment Management LLC boosted its stake in shares of Natus Medical by 160.5% in the second quarter. Confluence Investment Management LLC now owns 69,675 shares of the company’s stock valued at $2,634,000 after buying an additional 42,928 shares during the last quarter. Finally, Kalos Management Inc. bought a new stake in shares of Natus Medical during the second quarter valued at approximately $338,000. Institutional investors and hedge funds own 83.91% of the company’s stock.

Shares of Natus Medical Inc. (NASDAQ:BABY) traded down 4.52% during trading on Thursday, hitting $37.00. The stock had a trading volume of 611,867 shares. Natus Medical Inc. has a 52 week low of $29.54 and a 52 week high of $44.39. The firm has a 50 day moving average price of $36.62 and a 200-day moving average price of $39.37. The stock has a market capitalization of $1.20 billion, a price-to-earnings ratio of 30.08 and a beta of 1.10.

BABY has been the topic of several recent analyst reports. Zacks Investment Research lowered Natus Medical from a “buy” rating to a “hold” rating in a research note on Wednesday, September 28th. Benchmark Co. initiated coverage on Natus Medical in a research note on Tuesday, October 4th. They issued a “buy” rating and a $55.00 price target on the stock. Finally, Off Wall Street initiated coverage on Natus Medical in a research note on Friday, December 16th. They issued a “sell” rating on the stock. One equities research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $45.25.

In related news, insider James B. Hawkins purchased 10,000 shares of Natus Medical stock in a transaction that occurred on Friday, December 16th. The shares were acquired at an average cost of $35.20 per share, for a total transaction of $352,000.00. Following the transaction, the insider now directly owns 477,396 shares in the company, valued at $16,804,339.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Robert A. Gunst sold 3,250 shares of the firm’s stock in a transaction that occurred on Monday, October 24th. The stock was sold at an average price of $41.92, for a total value of $136,240.00. Following the transaction, the director now owns 51,150 shares in the company, valued at $2,144,208. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 47,664 shares of company stock worth $1,977,949. 4.80% of the stock is owned by corporate insiders.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).

Related posts

Leave a Comment